Literature DB >> 17966182

Treatment of lentigo maligna with imiquimod 5% cream.

Brent Hopson1, Donald Richey, F Paul Sajben.   

Abstract

Lentigo maligna (LM) is an in situ melanoma that occurs in sun-damaged skin on the head and neck of elderly patients. Surgical excision is the treatment of choice for LM. However, surgical options may be limited by the location of LM in cosmetically sensitive areas. We present a woman with a history of skin cancer with a large, asymmetrically pigmented lesion on her right superior cheek below her eyelid. The lesion had been present for approximately 15 years. Histologic analysis confirmed that the lesion was an LM. Imiquimod 5% cream was applied topically once daily. Approximately 5 months later, the previous LM had healed well and no new lesions were observed. Histologic clearance of the lentigo maligna was evident in skin biopsies. Imiquimod 5% cream appears effective in the treatment of lentigo maligna. We describe the treatment of a patient with facial LM with imiquimod 5% cream.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17966182

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  3 in total

1.  Cutaneous melanoma in situ: translational evidence from a large population-based study.

Authors:  Simone Mocellin; Donato Nitti
Journal:  Oncologist       Date:  2011-05-31

2.  Using topical imiquimod for the management of positive in situ margins after melanoma resection.

Authors:  Amrita S Pandit; Erik J Geiger; Stephan Ariyan; Deepak Narayan; Jennifer Nam Choi
Journal:  Cancer Med       Date:  2015-01-26       Impact factor: 4.452

3.  Successful treatment of lower eyelid melanoma in situ.

Authors:  Andrew A Gassman; Joyce Yuan; Justin Koh; Timothy A Miller
Journal:  Plast Reconstr Surg Glob Open       Date:  2014-06-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.